Trading in the shares of Herantis Pharma to commence today

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 11, 2014 at 2:15 AM

Trading in the shares of Herantis Pharma to commence today Herantis Pharma Plc Company release 11 June 2014 at 9:00 a.m. Not for release or distribution or publication in whole or in part in or into Australia, South Africa, Hong Kong, Japan, Canada or The United States or any other jurisdiction in which the release, distribution or publication would be unlawful. Herantis Pharma Plc ("Herantis" or "company") announced by way of a company release published on 12 May 2014 a directed share issue in which the company offers for subscribing a maximum of 1,600,000 new shares. In its release, the company also announced that it will apply for listing of its shares on First North Finland ("First North"), a multilateral trading facility operated by NASDAQ OMX Helsinki Ltd. The company issued a company release regarding the outcome of the share issue on 2 June 2014 and a company release regarding the final outcome on 4 June 2014. In the share issue, in total 1,364,770 shares were subscribed and paid for in accordance with the share issue terms and conditions. By virtue of the share issue, the number of issued shares in the company increased to 4,058,214 shares in total. The shares issued in the share issue were registered with the Trade Register on 6 June 2014. The shares carry shareholder rights in the company as of registration. Trading in the shares of Herantis will commence today 11 June 2014 on First North with the trading code HRTIS. The company's Certified Adviser under the First North rules is UB Capital Ltd. Herantis Pharma Plc Board of directors Further information: Herantis Pharma Plc, Pekka Simula, Managing Director, mobile: +358 40 7300 445 Certified Adviser: UB Capital Ltd, telephone +358 9 2538 0225 Herantis Pharma Plc Herantis Pharma Plc is a pharmaceutical company specialised in advancing scientific research into clinical research aiming at developing new drugs. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema. Disclaimer This release is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. Any such offer will be made solely on the basis of a prospectus to be published and registered with the Finnish Financial Supervisory Authority. This document is not an offer for sale nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area. The securities may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Herantis has not registered and will not register any part of its offering in the United States nor will it offer securities to the public in the United States. This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Securities in the company have not been, and will not be, registered under the applicable securities laws of Australia, Canada or Japan and may not be offered or sold within Australia, Canada or Japan or to, or for the account or benefit of, citizens or residents of Australia, Canada or Japan except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time. The company does not offer securities to the public in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland (each, a "Relevant Member State"), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, the shares may only be offered in Relevant Member States in circumstances not requiring the company to publish a prospectus as provided under the Directive 2003/71/EC. [HUG#1791756]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Solink Secures $100M: NYSE Sees Tech and Sports Moves

Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...

Yulin Dog Meat Ban: A Milestone in Animal Rights

Shockwaves from Yulin: A Landmark Victory Out of the blue, the news from Yulin is stirring emotions worldwide. All dog slaughterhouses in Yulin, a city notorious for its gruesome dog meat festival, have been reportedly demolished. The city plans to impose a ban on dog meat, a radical shift unimaginable a decade ago. For animal rights advocates, it's an invigorating shot...

Milwaukee Art Museum Secures $10 Million Preservation Fund

In a world where art meets aspiration, the Quadracci family’s latest $10 million gift to the Milwaukee Art Museum speaks volumes. With a vision to guarantee the future of architectural elegance, they’re making sure Santiago Calatrava’s stunning Quadracci Pavilion remains a cornerstone on Milwaukee’s skyline. For twenty-five years, this striking creation has not...

RPC Reports Q3 Loss Amid Revenue Growth Quirks

RPC Rides Out a Rough Quarter with Strategic Moves Ah, the oilfield services game—never a dull moment, right? RPC, Inc. just dropped their Q3 2026 results, and there’s a mixed bag to digest here. On the one hand, they saw a modest 1% uptick in revenue, hitting $467.7 million. But on the flip side, they're grappling with a hefty net loss of $41.9 million thanks to a...

DayOne's Bold Energy Moves With Sembcorp for Asia Growth

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Corgi Revamps Malpractice Insurance for Healthcare Sector

Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...

Max Stock Gears Up for Q3 Earnings Report Nov. 17

Max Stock's Q3 Earnings Anticipation Ah, it’s that time again—when we wait with bated breath for another round of quarterly earnings. Max Stock Ltd. (TASE: MAXO) is prepping to spill the beans on their third quarter 2026 performance, with a conference call scheduled for November 17. Big day? You bet. Who's Leading the Call? The brains behind the operation, CFO Paz Oz...

ACCULOAD: Aiming for Safer, Easier Boat Loading

Getting a boat onto a trailer? It can turn into a circus act if you're not careful. Visibility's shot, conditions change faster than a stock ticker, and alignment's like threading a needle blindfolded. Out comes ACCULOAD, a novel idea created by some intrepid inventor down in Slocomb, Ala, aiming to solve what’s been a pain point for boaters worldwide. What's ACCULOAD...

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

White House Photographer Reveals Unseen Historic Moments

You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...